Why the study?
Does metoprolol CR improve ventricular function, reduce activation of the renin-angiotensin systems, and prevent deaths in patients with ischemic and dilated cardiomyopathy?
Does metoprolol CR improve ventricular function, reduce activation of the renin-angiotensin systems, and prevent deaths in patients with ischemic and dilated cardiomyopathy?
Metoprolol CR provides mortality and physiological benefits in patients with ischemic and dilated cardiomyopathy already receiving ACE inhibitors or ARBs.
Supports metoprolol CR addition to ACEi/ARB in ischemic/dilated cardiomyopathy; confirms mortality benefit with ventricular and RAS improvements.
When added to ACE inhibitors, angiotensin II receptor antagonists, or both, the use of metoprolol CR improves ventricular function, reduces activation of the renin-angiotensin systems, and results in fewer deaths.
No takes yet. Share an insight, caveat, or question.
A 2000 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: